Paragon Care

What Paragon Care does

Paragon Care is an ASX-listed (ASX: PGC) healthcare distribution and medical technology company headquartered in Mount Waverley, Victoria, Australia, operating across Australia, New Zealand, and Asia. The company was formed through a transformative 2024 merger between Paragon Care Group and Clifford Hallam Healthcare (CH2), with roots tracing to CH2 Holdings, which was acquired by current Chairman Peter Lacaze and Executive Director David Collins in 2015. The business is organised around four strategic pillars: Specialty Diagnostics (including the Immulab blood bank IVD manufacturing subsidiary, the only Australian-owned manufacturer of In Vitro Diagnostics for blood banks), Specialty Devices (eye care, orthopaedics, and pain management), Capital and Consumables (urology, point of care, anaesthetics, ICU), and Service and Technology (equipment repair and maintenance delivered by a 50+ engineer field network).

The company generates revenue by distributing, and in some cases manufacturing, medical equipment, devices, consumables, and diagnostic products to enterprise healthcare providers. Distribution is supported by exclusive regional rights for several global partners, including Immucor (transfusion and transplant diagnostics), Body Vision Medical (LungVision AI imaging, TGA-approved March 2025), Coreline Soft (medical AI imaging, partnered February 2025), and Keeler (MacuMira Dry AMD therapy). Sovereign manufacturing capability at the purpose-built Immulab facility, plus a DVA RAP (Department of Veterans' Affairs) government supply contract, adds recurring-revenue and regulatory-defensibility dimensions to a primarily hardware-distribution model.

ParagonCare's go-to-market is enterprise field sales with direct customer engagement, supplemented by the ParagonCare Direct e-commerce platform. FY2026 revenue is guided to A$3.6b to A$3.7b, with analyst-implied margins around 1.58% net — consistent with a low-margin, high-velocity medical distribution model. The company continues to scale through M&A, most recently completing the Haju Medical acquisition on 2 April 2026, and is led by CEO and Managing Director Carmen Riley (CEO from 1 July 2025, MD from 1 March 2026) with continued majority ownership by Lacaze and Collins at 28.5% each.

Name

Paragon Care

Legal name

Clifford Hallam Healthcare Pty Limited trading as Paragon Care Australia

Website

https://paragoncare.com.au

Company type

Public

Founded year

2015

Operating status

Operating

Headcount range

51–100 employees

Short description

Paragon Care (ASX: PGC) is an Australian healthcare distributor and medical device company serving hospitals, laboratories, and clinics across Australia, New Zealand, and Asia via four pillars: Specialty Diagnostics, Specialty Devices, Capital and Consumables, and Service and Technology.

Ownership category

akta.pro rank

Product category

Medical Equipment Distribution and Healthcare Supplies

NAICS

Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (423450)

SIC

Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047), Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Services-Medical Laboratories (8071)

akta.pro primary industry

Durable Medical Equipment (DME) & Home Health Distribution (CRAOAHAF)

akta.pro secondary industries

Durable Medical Equipment (DME) Sales & Rentals (HSABAKAA), Medical & Hygiene Disposables (Underpads, Disposable Washcloths, Bed Bath Products) (CRADALAK), Sample Logistics, Biorepository & IVD Kit Management (Trial Support) (HLAGAEAI)

Keywords

• Medical equipment distribution
• Healthcare consumables supply
• Diagnostic reagents manufacturing
• Medical device distribution
• Healthcare wholesale services

Headquarters

HQ city

Scoresby

HQ country

Australia

HQ region

Oceania

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Healthcare Distribution and Medical Supplies: ParagonCare generates revenue through the distribution of medical equipment, devices, consumables, and diagnostic products to healthcare providers across Australia, New Zealand, and Asia. Revenue guidance for FY2026 is A$3.6b to A$3.7b.
2. Service and Maintenance: Equipment repair and maintenance services, preventative maintenance programs, electrical safety testing and commissioning, and total equipment management services delivered through a network of service engineers.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Core offering

ParagonCare distributes and supplies medical equipment, devices, consumables, and diagnostic products to healthcare providers across Australia, New Zealand, and Asia. The business operates across four strategic pillars — Specialty Diagnostics (including sovereign blood bank reagent manufacturing via Immulab), Specialty Devices (eye care and orthopaedics), Capital and Consumables (urology, point of care, anaesthetics, ICU), and Service and Technology (equipment repair and maintenance). It also runs the DVA RAP government program supplying approved products to Australian veterans.

Product overview

ParagonCare operates as a diversified healthcare technology and products company organized around four strategic pillars: Capital and Consumables, Specialty Devices, Specialty Diagnostics, and Service and Technology. The company distributes and manufactures a broad portfolio of medical equipment, devices, and consumables across healthcare sectors including critical care, dental, medical imaging, robotics, vision care, complementary medicine, diagnostic and scientific solutions, neonatal care, animal health, orthopaedics, surgical products, urology, and aesthetics. Key branded products include MacuMira (non-invasive microcurrent stimulation device for Dry AMD in partnership with Keeler), LungVision (AI-driven imaging for lung cancer diagnosis via Body Vision Medical), and Immulab (blood banking reagents - Australia's only domestically manufactured IVDs for blood banks). The Service and Technology pillar provides equipment repair, maintenance and technical support across Australia and New Zealand. Following the transformative merger with CH2 (Clifford Hallam Healthcare), ParagonCare expanded its product portfolio and market reach.

Differentiator

Problem solved

Functional benefit

Brands

• CH2: Healthcare distribution brand following merger with Clifford Hallam Healthcare
• Immulab
• Immuno
• MacuMira
• Western Biomedical
• Total Communications
• Vision
• Medical Devices
• Orthopaedics
• Scientific
• Service
• Complementary Medicine
• Animal Health

Products and services

• MacuMira A non-invasive microcurrent stimulation device for Dry AMD (Age-related Macular Degeneration) treatment, developed in partnership with Keeler. First and only TGA and Medsafe-listed microcurrent treatment for Dry AMD, distributed exclusively by ParagonCare in Australia and New Zealand. Targets optometrists, ophthalmologists, and eye care providers serving the 1.5 million+ Australians affected by AMD.
• LungVision AI-driven advanced imaging system for lung cancer diagnosis, developed by Body Vision Medical. ParagonCare is the exclusive Australian distribution partner, providing Australian hospitals and lung specialists with AI-powered bronchoscopy guidance and lung lesion detection.
• Immulab Blood Bank Diagnostic Reagents and IVDs Blood banking reagents, IVD diagnostics, and Immucor automation systems for blood donor screening and pre-/post-transplant typing and monitoring, supplied to blood banks and transplant diagnostic laboratories across Australia and New Zealand.
• Equipment Service and Maintenance Program Network of 50+ service engineers across Australia and New Zealand providing equipment repair, preventative maintenance, electrical safety testing, commissioning, and total equipment management for acute and ancillary care environments. Supports uptime and performance of customer equipment.
• DVA RAP Supply Program Department of Veterans' Affairs Rehabilitation Appliances Program supply contract delivering continence items, mobility supports, daily living aids, and specialized medical equipment to eligible Australian veterans holding Gold or White DVA cards.
• ParagonCare Direct (Online Ordering Platform) Dedicated e-commerce platform at direct.paragoncare.com.au enabling healthcare customers to place orders online for ParagonCare's range of medical products, devices, and consumables.

Quantifiable outcome

• Over 1 million blood donations screened annually in Australia using ParagonCare/Immulab solutions
• +2 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature2 records

Partnerships

Six partnerships are on record, tiered minor and core.

• Haju MedicalminorStrategic or Co-development Partner · 2 April 2026ParagonCare completed acquisition of Haju Medical, expanding product portfolio and market presence.
• Body Vision MedicalcoreChannel Partner/ Reseller/ Distributor · 12 March 2025ParagonCare is the exclusive distribution partner for Body Vision Medical's LungVision system, an AI-driven advanced imaging technology for lung cancer diagnosis. Received regulatory approval in Australia in March 2025.
• Coreline SoftcoreChannel Partner/ Reseller/ Distributor · 19 February 2025ParagonCare Australia exclusive partner for Coreline Soft, a pioneer in medical artificial intelligence (AI) imaging. Strategic partnership announced in February 2025 for Australian market.
• ImmucorcoreChannel Partner/ Reseller/ Distributor · 1 January 2021Immulab (ParagonCare subsidiary) has exclusive distribution relationship with Immucor for Transfusion Diagnostics in Australia and New Zealand since 2014. Expanded to include Transplant Diagnostic products from early 2021. Immucor's transplant diagnostics division provides assays for pre-transplant typing, screening and post-transplant monitoring.
• KeelercoreTechnology or IntegrationGlobal partnership between MacuMira and Keeler to expand Dry AMD therapy. Includes launch in Australia and New Zealand distributed exclusively by ParagonCare, with additional markets to follow.
• CH2 (Clifford Hallam Healthcare)coreStrategic or Co-development PartnerTransformative merger between Paragon Care Group and Clifford Hallam Healthcare (CH2) to create ParagonCare, a leading healthcare wholesaler and distributor. Expanded product portfolio across all healthcare sectors.

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

Others

• Ramsay Health Care: Largest private hospital operator in Australia and a major ParagonCare end-customer. Comparable as a participant in the ANZ healthcare ecosystem that consumes the types of products PGC distributes and services, useful for demand-side context.

Direct peers

• Henry Schein: US-listed distributor of medical, dental and animal health products. Comparable business model - multi-vertical healthcare distribution with a strong consumables franchise - making it a useful global template for ParagonCare's go-to-market.
• Ansell: Australian-listed global manufacturer of medical and industrial protective equipment. Comparable in its ANZ medtech base, distribution into hospitals and surgical settings, and overlapping product categories (surgical, consumables).
• EBOS Group: NZ-headquartered healthcare products and animal care distributor with major ANZ exposure. Closest direct comparable to ParagonCare across medical device distribution, DME, and consumables, including overlapping customer base of hospitals and pharmacies.

Regional players

• Fisher & Paykel Healthcare: NZ-based manufacturer of respiratory care, acute care and homecare products. Comparable in its ANZ medtech orientation, overlap with ParagonCare's Capital & Consumables and respiratory product exposure, and similar end-customers in hospitals.

Broad incumbents

• Healius: Australian healthcare services and diagnostics operator (pathology, imaging, day hospitals). Comparable as an incumbent Australian healthcare group with both diagnostic capabilities and broad provider relationships, though services-led rather than distribution-led.
• Cochlear: Australian-listed global medical device company focused on implantable hearing solutions. Comparable as a high-profile ASX-listed medical device company with strong ANZ distribution heritage, though operating in a much narrower product niche.
• Sonic Healthcare: Largest Australian-listed diagnostics and pathology provider with global operations. Comparable through its diagnostic testing footprint and use of Immulab-type IVD supply chains, though at far greater scale and with a different end-market mix.
• Cardinal Health: US-listed Fortune 500 medical products distributor. Comparable as a global benchmark for the medical/surgical distribution and DME business model that ParagonCare operates at a regional scale.

Emerging players

• Nanosonics: Australian-listed infection prevention medtech with a single flagship platform (trophon). Comparable as an ANZ medtech commercialiser that relies on hospital channel distribution, similar to ParagonCare's go-to-market for specialty devices.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/paragon-care-ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A5 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Paragon Care